Brainomix and Bridge Biotherapeutics, Inc. Announce Partnership to Use Brainomix’s AI-Powered e-ILD Software for Automated Assessment of Idiopathic Pulmonary Fibrosis (IPF)

  • Partnership will focus on quantitative analysis of imaging data by Brainomix AI (e-ILD) software in Phase 2 study of novel autotaxin inhibitor, BBT-877, in pulmonary fibrosis idiopathic (IPF)

OXFORD, England, September 7, 2022 /PRNewswire/ — Brainomix, the AI-powered medical technology solutions company, and Bridge Biotherapeutics, Inc., a South Korean clinical-stage biotechnology company focused on developing novel drugs for cancer, fibrosis and inflammation, today announced a new partnership to provide quantitative imaging biomarker analysis in the Phase 2 study of the novel autotaxin inhibitor BBT-877, which has been designed to to assess the safety, tolerability and efficacy of BBT-877 in idiopathic pulmonary fibrosis (IPF).

As part of the partnership, Brainomix will leverage its e-ILD (automated artificial intelligence software) technology which has been trained to process high-resolution chest computed tomography (HRCT) data in patients with interstitial lung disease, including IPF and other conditions that cause progressive pulmonary fibrosis. Both companies aim to collect high-quality imaging data that will be used to explore the efficacy of BBT-877 and to demonstrate the value that Brainomix’s AI-based imaging biomarkers offer as new endpoints. evaluation for future IPF clinical trials.

IPF clinical trials typically rely on serial physiological measurements of forced vital capacity (FVC) as endpoints, which can be highly variable from day to day for an individual patient. Automated quantitative imaging powered by AI has the potential to dramatically improve trial design, improve the odds of identifying a positive treatment response, and accelerate the translation of new treatments into clinical practice. By using proprietary, patented objective imaging biomarkers and tracking changes over time, Brainomix will provide Bridge Biotherapeutics with valuable insights and additional data on the efficacy and mechanism of action of BBT-877.

Brainomix is ​​an established leader in AI imaging biomarkers, having developed and commercialized the world’s first fully automated AI solution for stroke assessment (e-Stroke). Building on this heritage and success, Brainomix has expanded beyond stroke into areas where there are similar unmet needs and opportunities to improve diagnosis and treatment. Brainomix has a long history of partnering with pharmaceutical companies in the area of ​​stroke and lung cancer, and this new partnership with Bridge Biotherapeutics Inc. marks another step forward in expanding the value that Brainomixit is AI expertise can bring conditions outside the brain.

“We are very pleased to announce this partnership with Bridge Biotherapeutics, Inc., where our existing technology platform and expertise will be leveraged to provide an objective evaluation of the efficacy of BBT-877 in IPF. AI-powered imaging is becoming an increasingly critical component of studies in IPF and more broadly in non-IPF interstitial lung disease, where it has the potential to improve trial knowledge and complement existing methodology and assessment criteria,” said Dr. Peter GeorgeMedical Director (Respiratory) at Brainomix and Clinical Manager of the Interstitial Lung Disease Unit at the Royal Brompton Hospital.

Agnes JungHead of Project Management at Bridge Biotherapeutics, said, “We believe the partnership with Brainomix will allow us to generate additional efficacy data from our clinical study in patients with IPF based on their technology. imaging and their combined expertise. to earlier prediction of treatment response in patients as the partnership continues.”

This partnership will build on Brainomix’s existing offering to pharmaceutical and medical partners, where the development and deployment of AI-powered biomarkers drive value during clinical development and can drive wider adoption of existing therapies and new.

About Brainomix

Brainomix specializes in creating AI-powered software solutions to enable precision medicine to make better treatment decisions in stroke, pulmonary fibrosis and cancer. With origins as a spin-out of the Oxford University, Brainomix is ​​a growing commercial enterprise that has pioneered award-winning imaging biomarkers and software solutions used in more than 30 countries around the world. Its first product, the e-Stroke platform, offers clinicians the most comprehensive stroke imaging solution, accelerating treatment times and improving patient functional independence. Its pipeline includes new imaging biomarkers for better treatment of pulmonary fibrosis and cancer, and its technology is used by pharmaceutical companies to improve the success of clinical trials.

A private company, headquartered in Oxford, United Kingdom Brainomix investors include Boehringer Ingelheim Venture Fund, Parkwalk Advisors, Tencent holdings and Oxford University Innovation Fund.

To learn more about Brainomix and its technology, visit and follow us on Twitter, LinkedIn and Facebook.

About Bridge Biotherapeutics Inc.

Bridge Biotherapeutics Inc. is a publicly traded clinical-stage biotechnology company domiciled in the Republic of Korea with offices in the United States and China. Founded in 2015, Bridge Biotherapeutics is committed to the discovery and development of new therapies for diseases with unmet medical needs, including cancer, ulcerative colitis and various fibrotic diseases. The Company’s pipeline includes BBT-401, a first-in-class Pellino-1 inhibitor for the treatment of ulcerative colitis; BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases, including idiopathic pulmonary fibrosis (IPF); and BBT-176, a potent targeted therapy for non-small cell lung cancer (NSCLC) with EGFR C797S triple mutations.

For more information, please visit


At Brainomix
Jeff Wyrtzenmarketing and business development director
[email protected]
+44 (0)7927 164210
T +44 (0)1865 582730

Media inquiries
Sue CharlesCharles Consultants
[email protected]
+44 (0)7968 726585




Comments are closed.